EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 424 filers reported holding EXELIXIS INC in Q4 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,030,566 | +37.8% | 90,211 | +45.3% | 0.00% | 0.0% |
Q1 2024 | $1,473,292 | +34.8% | 62,085 | +36.6% | 0.00% | 0.0% |
Q4 2023 | $1,092,768 | -62.8% | 45,459 | -65.7% | 0.00% | -66.7% |
Q3 2023 | $2,934,091 | +205.8% | 132,411 | +164.1% | 0.00% | +200.0% |
Q2 2023 | $959,333 | +4.1% | 50,135 | +4.2% | 0.00% | 0.0% |
Q1 2023 | $921,151 | -71.4% | 48,127 | -76.5% | 0.00% | -75.0% |
Q4 2022 | $3,222,100 | +2.7% | 204,448 | +3.3% | 0.00% | -20.0% |
Q3 2022 | $3,138,000 | +257.4% | 197,934 | +372.4% | 0.01% | +400.0% |
Q2 2022 | $878,000 | +40.5% | 41,902 | +52.3% | 0.00% | 0.0% |
Q1 2022 | $625,000 | +105.6% | 27,517 | +67.2% | 0.00% | – |
Q4 2021 | $304,000 | -54.7% | 16,460 | -47.7% | 0.00% | -100.0% |
Q3 2021 | $671,000 | -32.3% | 31,474 | -42.0% | 0.00% | 0.0% |
Q2 2021 | $991,000 | +50.2% | 54,223 | +86.8% | 0.00% | 0.0% |
Q1 2021 | $660,000 | +77.9% | 29,030 | +56.1% | 0.00% | – |
Q4 2020 | $371,000 | -46.4% | 18,603 | -34.2% | 0.00% | -100.0% |
Q3 2020 | $692,000 | +54.5% | 28,254 | +49.7% | 0.00% | 0.0% |
Q2 2020 | $448,000 | -34.8% | 18,868 | -52.1% | 0.00% | -50.0% |
Q1 2020 | $687,000 | +3.3% | 39,359 | +5.3% | 0.00% | +100.0% |
Q4 2019 | $665,000 | -52.4% | 37,387 | -36.4% | 0.00% | -66.7% |
Q1 2019 | $1,398,000 | +78.8% | 58,755 | +46.9% | 0.00% | +200.0% |
Q4 2018 | $782,000 | -70.1% | 40,000 | -72.9% | 0.00% | -75.0% |
Q3 2018 | $2,617,000 | -33.7% | 147,865 | +13.9% | 0.00% | -33.3% |
Q4 2017 | $3,948,000 | +576.0% | 129,871 | +231.6% | 0.01% | +500.0% |
Q4 2016 | $584,000 | +3793.3% | 39,168 | +281.0% | 0.00% | – |
Q4 2014 | $15,000 | -80.8% | 10,280 | -55.0% | 0.00% | – |
Q2 2014 | $78,000 | -3.7% | 22,829 | +0.0% | 0.00% | – |
Q1 2014 | $81,000 | -36.7% | 22,828 | +9.8% | 0.00% | – |
Q4 2013 | $128,000 | -85.6% | 20,800 | -86.4% | 0.00% | -100.0% |
Q3 2013 | $888,000 | -38.8% | 152,644 | -52.2% | 0.00% | -50.0% |
Q2 2013 | $1,451,000 | -1.8% | 319,644 | 0.0% | 0.00% | -20.0% |
Q1 2013 | $1,477,000 | -14.0% | 319,644 | -14.9% | 0.01% | -28.6% |
Q4 2012 | $1,717,000 | -5.2% | 375,800 | 0.0% | 0.01% | 0.0% |
Q3 2012 | $1,811,000 | -57.4% | 375,800 | -51.1% | 0.01% | -63.2% |
Q2 2012 | $4,251,000 | +6.7% | 768,800 | 0.0% | 0.02% | +11.8% |
Q1 2012 | $3,983,000 | – | 768,800 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |